$363.84▴ 1.25%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 13% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Krystal Biotech, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Why Tutor Perini Stock Trounced the Market on Tuesday
3 Soaring Stocks That May Have More Upside Ahead